[Retracted] Efficacy, Safety, and Tumor Marker Inhibition of Apatinib Combined with Conventional Chemotherapy Regimens for Patients with Advanced Triple-Negative Breast Cancer

Table 4

The occurrence rate of adverse reactions between the conventional and combined groups after treatment.

Adverse reaction	Group	Neutropenia	Leukocytopenia	Pain	Gastrointestinal reaction	Hypertension	Weakness	Oral mucositis	Hand-foot syndrome
Grade I-II	Conventional (n = 75)	22	35	34	35	22	33	16	26
	Combined (n = 75)	22	34	30	33	21	31	13	25
χ^2		1.515	1.194	1.175	1.216	1.271	1.073	1.056	1.162
		0.171	0.186	0.272	0.248	0.319	0.215	0.137	0.104
Grade III-IV	Conventional (n = 75)	7	0	9	17	16	2	4	3
	Combined (n = 75)	8	1	8	16	17	3	5	3
χ^2		1.115	1.074	1.213	1.072	1.082	1.061	1.077	1.092
		0.215	0.218	0.191	0.143	0.162	0.214	0.117	0.241